a regulatory subunit of cAMP-regulated protein kinase. The inactive form of the enzyme is composed of two regulatory chains and two catalytic chains. Activation by cAMP produces two active catalytic monomers and a regulatory dimer that binds four cAMP molecules. Four types of regulatory chains are found: I-alpha, I-beta, II-alpha, and II-beta. Their expression varies among tissues and is in some cases constitutive and in others inducible. Interacts with RFC2: the complex may be involved in cell survival. Defects in PRKAR1A are the cause of Carney complex type 1 (CNC1). CNC is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas. Note: This description may include information from UniProtKB.
Protein type: Protein kinase, regulatory subunit
Cellular Component: protein complex; membrane; plasma membrane; cytosol; neuromuscular junction; AMP-activated protein kinase complex; cAMP-dependent protein kinase complex
Molecular Function: protein binding; cAMP-dependent protein kinase inhibitor activity; ubiquitin protein ligase binding; cAMP-dependent protein kinase regulator activity; cAMP binding
Biological Process: epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; nerve growth factor receptor signaling pathway; water transport; activation of protein kinase A; female meiosis; cardiac muscle cell proliferation; sarcomere organization; signal transduction; regulation of transcription from RNA polymerase II promoter; mesoderm formation; phospholipase C activation; negative regulation of meiosis; energy reserve metabolic process; innate immune response; blood coagulation; transmembrane transport; regulation of insulin secretion
Alt. Names/Synonyms: cAMP-dependent protein kinase regulatory subunit RIalpha; cAMP-dependent protein kinase type I-alpha regulatory chain; cAMP-dependent protein kinase type I-alpha regulatory subunit; CAR; CNC; CNC1; DKFZp779L0468; KAP0; MGC17251; PKR1; PPNAD1; PRKAR1; PRKAR1A; protein kinase A type 1a regulatory subunit; protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1); Tissue-specific extinguisher 1; TSE1
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.